151 related articles for article (PubMed ID: 36544182)
21. BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group.
Bu H; Chen J; Li Q; Hou J; Wei Y; Yang X; Ma Y; He H; Zhang Y; Kong B
J Obstet Gynaecol Res; 2019 Nov; 45(11):2267-2274. PubMed ID: 31411802
[TBL] [Abstract][Full Text] [Related]
22. Secondary Somatic Mutations Restoring
Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O'Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL;
Cancer Discov; 2017 Sep; 7(9):984-998. PubMed ID: 28588062
[TBL] [Abstract][Full Text] [Related]
23. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
24. Location of Mutation in
Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
[No Abstract] [Full Text] [Related]
25. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
[TBL] [Abstract][Full Text] [Related]
26. The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
Wu X; Wu L; Kong B; Liu J; Yin R; Wen H; Li N; Bu H; Feng Y; Li Q; Lu X; Wei J; Zhu X; Mills J; Ellison G; Gutjahr T; Liu Y
Int J Gynecol Cancer; 2017 Oct; 27(8):1650-1657. PubMed ID: 28692638
[TBL] [Abstract][Full Text] [Related]
27. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC
J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557
[TBL] [Abstract][Full Text] [Related]
28. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
29. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
30. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.
Manning-Geist B; Gordhandas S; Liu YL; Zhou Q; Iasonos A; Da Cruz Paula A; Mandelker D; Long Roche K; Zivanovic O; Maio A; Kemel Y; Chi DS; O'Cearbhaill RE; Aghajanian C; Weigelt B; Chui MH; Grisham RN
Clin Cancer Res; 2022 Oct; 28(20):4456-4465. PubMed ID: 35443055
[TBL] [Abstract][Full Text] [Related]
31. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
32. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
33. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
34. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
[TBL] [Abstract][Full Text] [Related]
35. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
37. Germline and tumor
Ji G; Yao Q; Bao L; Zhang J; Bai Q; Zhu X; Tu X; Bi R; Zhou X
Ann Transl Med; 2021 Mar; 9(6):453. PubMed ID: 33850850
[TBL] [Abstract][Full Text] [Related]
38. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
[TBL] [Abstract][Full Text] [Related]
39. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
40. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
